# Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

> **NCT04052204** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 3 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Metastatic Castration Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** avelumab
- **DRUG:** Bempegaldesleukin
- **DRUG:** talazoparib
- **DRUG:** enzalutamide

## Key facts

- **NCT ID:** NCT04052204
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-30
- **Primary completion:** 2020-09-29
- **Final completion:** 2020-09-29
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not provide additional clinical benefit over current or future Standard of Care in the different therapeutic indications that this trial was to evaluate.
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04052204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04052204, "Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04052204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*